今年9月12日,康诺亚-B(02162)宣布其核心产品司普奇拜单抗(康悦达®)在国内获批上市,成为继赛诺菲明星产品度普利尤单抗之后全球IL-4Rα靶点上的第二款药物。此时正好赶上港股9月下旬上涨行情,在恒指大盘和港股医药板块的带动下,康诺亚在短暂调整后走出一波上涨行情,股价从9月24日低点34.10港元,一路拉升至10月7日盘中的区间高点47.50港元,区间涨幅达39.30%。虽然后续出现整体回调...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.